Spherix Global Insights Launches Obesity Franchise as Weight Management Impacts Commercial Strategy Across Related Markets

Exton, PA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights, an independent market intelligence and advisory firm serving the global life sciences industry, today announced the launch of its Obesity Franchise.  The launch brings Spherix’s existing obesity research into a focused franchise, connecting it with the firm’s established gastroenterology/MASH and nephrology/cardiorenal expertise while creating opportunities to expand its publication portfolio and advisory capabilities as treatment decisions increasingly span obesity, cardiometabolic health, and kidney disease.

Obesity is increasingly influencing treatment strategies and commercial opportunities across MASH, CKD-ND, and related cardiometabolic conditions. For commercial and medical teams, this overlap raises questions about where treatment decisions intersect, how responsibilities differ across specialties, and how payer policies influence access. Spherix’s Obesity Franchise places these questions within a focused research and advisory offering.

The franchise connects Spherix’s obesity research with expertise from its Gastroenterology and Nephrology teams. This collaboration helps clients understand the specific treatment and access considerations within obesity, MASH, and CKD-ND, while identifying where decisions across these markets intersect. Research across physician, patient, and payer perspectives examines therapy adoption and sequencing, treatment burden and persistence, as well as formulary and coverage decisions. Together, these findings help clients understand how clinical preferences, patient experiences, and access requirements influence the opportunities for new and established therapies. This integrated view also supports organizations approaching these markets through a cardiovascular-kidney-metabolic (CKM) framework.

For clients, these insights support decisions about where to compete, how to differentiate, and which barriers to address. Connecting physician prescribing decisions with patient experiences and payer requirements helps teams refine brand positioning, prioritize evidence needs, and focus on engagement strategies. Coverage across related conditions also helps clients evaluate how changes in one market may influence adoption and access in another.

Led by Jim Hickey, Franchise Head, Gastroenterology and Obesity, the team provides syndicated intelligence and tailored advisory support for development, launch, positioning, and market access decisions. Clients can draw on therapeutic expertise and research tailored to specific strategic questions, from understanding prescribing patterns to identifying barriers to treatment adoption and continuity.

Spherix’s established Nephrology Franchise, led by Kari McCarthy, provides an additional layer of expertise across the evolving obesity and cardiorenal landscape. Associated research titles examine the challenges of treating patients with non-dialysis chronic kidney disease (CKD-ND) and cardiorenal disease, including treatment patterns, unmet needs, and the clinical and access dynamics shaping adoption. Together with Spherix’s obesity research, these insights give clients a broader view of how weight management is increasingly influencing treatment strategies across interconnected metabolic, cardiovascular, and kidney diseases.

“Success in obesity requires understanding how clinical promise translates into prescribing, access, and sustained treatment,” explained Hickey. “As opportunities extend into MASH and kidney disease, companies cannot assume that the same evidence, positioning, or engagement strategy will resonate across specialties. Expanding our research helps clients identify where those differences matter and make more informed decisions about their brands.”

Establishing the Obesity Franchise gives clients a clearer point of access to Spherix’s research and specialists while positioning the firm to deepen its coverage of an increasingly interconnected area of care.

For more information, visit Spherix Global Insights’ Obesity Franchise.

About Spherix Global Insights

Spherix Global Insights is a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By combining physician, patient, and payer perspectives into an integrated view, Spherix helps brand teams, market access stakeholders, and investors understand how a specialty market actually behaves, not how any one stakeholder describes it.

The firm operates ten dedicated therapeutic franchises – Dermatology, Gastroenterology, Hematology, Nephrology, Neuroscience, Obesity, Oncology, Ophthalmology, Respiratory and Rheumatology – plus a Market Access team. Each franchise is staffed by hyper-focused experts who track these markets full-time, drawing on independently curated communities of vetted specialists, patients, and payers to deliver quarterly trending, launch tracking, chart audits, and KOL synthesis.

Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for more than a decade for leading brands, industry media, financial analysts, and patient advocacy groups.

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.

NOTICE: All company, brand, or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insights’ analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.

Jim Hickey, Franchise Head, Gastroenterology & Obesity
Spherix Global Insights
484-879-4284
james.hickey@spherixglobalinsights.com